Welcome to the front desk of the JAVIS Community, we're glad to have you here.

If you only bookmark one space, make it this one.

This is where you’ll see what’s changing in the supply chain landscape, what’s new in the industry, and what you need to know to keep mastering the JAVIS community confidently.

Here’s what you’ll find here:

Short, skimmable industry trends and wins to stay updated

🧩 Notes on behaviour changes that might affect your workflows.

🧭 Pointers to new resources, categories, and programs in the community.

How to use this space:

If you’re new, read the pinned welcome posts first.

Each time you log in, skim the most recent announcement so you’re operating on the latest truth.

If an update raises a question, reply directly in that thread so others can see the clarification too.

Higher near-term costs, longer-term structural shifts expected.

The new U.S.–EU pharma tariff agreement, which caps tariffs at 15% and shields EU drugs from additional Section 232 duties, is set to raise near-term costs by nearly $19 billion. Insurers are likely to absorb the initial impact before prices rise for consumers. With 60% of U.S. drug imports coming from Europe, analysts warn ongoing legal uncertainty around tariff authority could delay investment and trigger a gradual reconfiguration of global pharmaceutical production.

Read More